Details for New Drug Application (NDA): 016860
✉ Email this page to a colleague
NDA 016860 describes ESKALITH, which is a drug marketed by Noven Therap and Jds Pharms and is included in three NDAs. Additional details are available on the ESKALITH profile page.
The generic ingredient in ESKALITH is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
The generic ingredient in ESKALITH is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 016860
| Tradename: | ESKALITH |
| Applicant: | Noven Therap |
| Ingredient: | lithium carbonate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 016860
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 300MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
